Drug Profile
DS 7080a - Daiichi Sankyo Company
Alternative Names: DS 7080; DS-7080aLatest Information Update: 28 Dec 2018
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Inc
- Class Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Diabetic macular oedema
Most Recent Events
- 28 Dec 2018 No recent reports of development identified for phase-I development in Age-related-macular-degeneration(Combination therapy) in USA (Intravitreous, Injection)
- 28 Dec 2018 No recent reports of development identified for phase-I development in Age-related-macular-degeneration(Monotherapy) in USA (Intravitreous, Injection)
- 28 Dec 2018 No recent reports of development identified for phase-I development in Diabetic-macular-oedema(Combination therapy) in USA (Intravitreous, Injection)